-
Je něco špatně v tomto záznamu ?
Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049)
E. Bosch, A. Nyboe Andersen, P. Barri, JA. García-Velasco, P. de Sutter, M. Fernández-Sánchez, H. Visnova, BM. Klein, B. Mannaerts, JC. Arce,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
26202150
DOI
10.1111/cen.12864
Knihovny.cz E-zdroje
- MeSH
- antimülleriánský hormon krev MeSH
- dospělí MeSH
- fertilizace in vitro MeSH
- folikuly stimulující hormon krev terapeutické užití MeSH
- indukce ovulace metody MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- těhotenství MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVE: To study the association between serum anti-Müllerian hormone (AMH) levels and follicular development and endocrine responses induced by increasing doses (5·2-12·1 μg/day) of a novel recombinant human FSH (rhFSH, FE 999049) in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in a GnRH antagonist protocol. DESIGN: Secondary analysis of a randomized controlled trial with stratified randomization according to AMH (lower stratum: 5·0-14·9 pmol/l; higher stratum: 15·0-44·9 pmol/l). PATIENTS: Infertile women of good prognosis (n = 265). MEASUREMENTS: Follicular development and endocrine parameters during controlled ovarian stimulation (COS) with rhFSH. RESULTS: Serum FSH levels increased with increasing rhFSH doses and steady-state levels for each dose were similar in both AMH strata. In the whole study population, significant (P < 0·001) positive dose responses were observed for the number of follicles ≥ 12 mm, and serum levels of oestradiol, inhibin B, inhibin A and progesterone at end of stimulation. In comparison with the higher AMH stratum, patients in the lower AMH stratum had significantly different slopes of the dose-response curves for these hormones, and no clear dose-related increase was observed for the number of follicles in these patients. CONCLUSIONS: Dose-response relationships between rhFSH and follicular development and endocrine parameters are significantly different for IVF/ICSI patients with lower and higher serum AMH levels at start of COS.
Fertility Clinic Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17001085
- 003
- CZ-PrNML
- 005
- 20170113125742.0
- 007
- ta
- 008
- 170103s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cen.12864 $2 doi
- 024 7_
- $a 10.1111/cen.12864 $2 doi
- 035 __
- $a (PubMed)26202150
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bosch, Ernesto $u IVI Valencia, Valencia, Spain.
- 245 10
- $a Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049) / $c E. Bosch, A. Nyboe Andersen, P. Barri, JA. García-Velasco, P. de Sutter, M. Fernández-Sánchez, H. Visnova, BM. Klein, B. Mannaerts, JC. Arce,
- 520 9_
- $a OBJECTIVE: To study the association between serum anti-Müllerian hormone (AMH) levels and follicular development and endocrine responses induced by increasing doses (5·2-12·1 μg/day) of a novel recombinant human FSH (rhFSH, FE 999049) in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in a GnRH antagonist protocol. DESIGN: Secondary analysis of a randomized controlled trial with stratified randomization according to AMH (lower stratum: 5·0-14·9 pmol/l; higher stratum: 15·0-44·9 pmol/l). PATIENTS: Infertile women of good prognosis (n = 265). MEASUREMENTS: Follicular development and endocrine parameters during controlled ovarian stimulation (COS) with rhFSH. RESULTS: Serum FSH levels increased with increasing rhFSH doses and steady-state levels for each dose were similar in both AMH strata. In the whole study population, significant (P < 0·001) positive dose responses were observed for the number of follicles ≥ 12 mm, and serum levels of oestradiol, inhibin B, inhibin A and progesterone at end of stimulation. In comparison with the higher AMH stratum, patients in the lower AMH stratum had significantly different slopes of the dose-response curves for these hormones, and no clear dose-related increase was observed for the number of follicles in these patients. CONCLUSIONS: Dose-response relationships between rhFSH and follicular development and endocrine parameters are significantly different for IVF/ICSI patients with lower and higher serum AMH levels at start of COS.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antimülleriánský hormon $x krev $7 D054304
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fertilizace in vitro $7 D005307
- 650 _2
- $a folikuly stimulující hormon $x krev $x terapeutické užití $7 D005640
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indukce ovulace $x metody $7 D010062
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nyboe Andersen, Anders $u Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- 700 1_
- $a Barri, Pedro $u IU Dexeus, Barcelona, Spain.
- 700 1_
- $a García-Velasco, Juan Antonio $u IVI Madrid, Madrid, Spain.
- 700 1_
- $a de Sutter, Petra $u Universitair Ziekenhuis, Gent, Belgium.
- 700 1_
- $a Fernández-Sánchez, Manuel $u IVI Sevilla, Sevilla, Spain.
- 700 1_
- $a Visnova, Hana $u IVF CUBE SE, Prague, Czech Republic.
- 700 1_
- $a Klein, Bjarke M $u Global Biometrics, Global Clinical & Non-Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
- 700 1_
- $a Mannaerts, Bernadette $u Reproductive Health, Global Clinical & Non-Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
- 700 1_
- $a Arce, Joan-Carles $u Reproductive Health, Global Clinical & Non-Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark. $7 gn_A_00008124
- 773 0_
- $w MED00009474 $t Clinical endocrinology $x 1365-2265 $g Roč. 83, č. 6 (2015), s. 902-12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26202150 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170113125843 $b ABA008
- 999 __
- $a ok $b bmc $g 1180225 $s 961652
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 83 $c 6 $d 902-12 $e 20150903 $i 1365-2265 $m Clinical endocrinology $n Clin Endocrinol (Oxf) $x MED00009474
- LZP __
- $a Pubmed-20170103
